Molbio’s Truenat technology gets recognition at World Health Assembly

Molbio’s portable Truenat system praised for its impact on TB diagnosis and healthcare accessibility, expanding global reach to over 80 countries

New Delhi: Molbio received high praise at the 77th World Health Assembly in Geneva for its innovative Truenat technology.
The assembly, which is the decision-making body of the World Health Organization (WHO), brought together delegations from all WHO member states to discuss key health agendas.
The Global Fund, in collaboration with WHO, highlighted India’s commitment to eliminating tuberculosis (TB) through mass awareness and intensive monitoring programs using digital technologies. India’s pioneering TB initiatives, including Truenat machines and handheld X-ray devices for challenging environments, were lauded as exemplary models for global adoption. Union Health Secretary Apurva Chandra, attending the convention, urged the Global Fund to continue supporting the TB program to enhance public health system capacities.
Truenat, a real-time quantitative micro-PCR system developed by Molbio, enables rapid molecular diagnostics at the point of care. This portable, battery-operated technology can be used in various settings, from primary health centers to remote field locations, decentralizing and democratizing healthcare access. The WHO-approved device is infrastructure-independent and provides comprehensive disease diagnosis solutions, even in the harshest conditions and remotest geographies. Truenat’s innovative approach represents a significant advancement in the global fight against infectious diseases.
Molbio’s Founder and CEO, Sriram Natarajan, expressed, “As a CEO, witnessing our homegrown product win global validation is not just a testament to our innovation but a reaffirmation of our commitment to excellence. At Molbio, our commitment lies in facilitating enhanced medicine, alleviating patient suffering, staying attuned to patient needs, and perpetually innovating to introduce new technologies for societal betterment. It is a proud moment that underscores the power of relentless pursuit and collective dedication towards creating impactful solutions that resonate on a global scale”.
As India’s largest in-vitro diagnostics (IVD) company, Molbio has over 10,000 installations across public and private sectors. Expanding its global footprint, Molbio now distributes to over 80 countries, demonstrating its commitment to delivering cost-effective, cutting-edge technologies to patients in the most remote regions of the world.